Rodríguez-Jiménez P, Reolid A, Chicharro P, Navarro R, Llamas-Velasco M, Aragüés M

Language: Spanish
References: 34
Page: 112-118
PDF size: 309.61 Kb.

ABSTRACT

Introduction: Angiosarcoma is a rare malign cutaneous tumor with unknow aetyology that accounts from ‹ 1% of soft tissue sarcomas in adults. Up to nowadays, there is not a standard succesful treatment, specially for the non operable cases. Aim: To report a single center experience and at the same time unify the cases and series treated with novel treatments that aim new molecular targets. Material and methods: We have performes a retrospective study of 12 angiosarcoma patients diagnosed in between 1993 and 2016 in our centre. The following data was gathered: age, gender, comorbilities, location, treatment and outcome. Descriptive statystical analysis was performed by percentage, mean and age range. Results: Our mean age was 77.2 years old, 80% were male and 80% of tumors were located on head and neck. Standard treatment in our centre was (62%). Five years total survival was 20% with a mean survival of 39.6 months. We did not observe that any of the studied variables were associated with better prognosis. Conclusion: In our series we observe a mortality similar to described in previous larger series, in spite of a minor use of chemotherapy. Finally the new therapeutic lines show promising results for the future.

REFERENCES

1. Beyeler M, Kempf W, Hafner J, Burg G, Dummer R. The spectrum of mesenchymal skin neoplasms reflected by the new WHO classification. Onkologie. 2004; 27 (4): 401-406.

2. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948; 1 (1): 64-81.

3. Goette DK, Detlefs RL. Postirradiation angiosarcoma. J Am Acad Dermatol. 1985; 12 (5 Pt 2): 922-926.

4. Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987; 59 (5): 1046-1057.

5. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999; 154 (2): 385-394.

6. Requena L, Santonja C, Stutz N, Kaddu S, Weenig RH, Kutzner H et al. Pseudolymphomatous cutaneous angiosarcoma: a rare variant of cutaneous angiosarcoma readily mistaken for cutaneous lymphoma. Am J Dermatopathol. 2007; 29 (4): 342-350.

7. Sullivan HC, Edgar MA, Cohen C, Kovach CK, HooKim K, Reid MD et al. The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases. J Clin Pathol. 2015; 68 (1): 44-50.

8. Kak I, Sadikovic B, Pare G, Corbett T, Popovic S. Abstract 521: c-MYC as a differentiating marker between angiosarcoma and atypical vascular lesion. Cancer Research. 2016; 76 (14 Supplement): 521.

9. Paolino G, Lora V, Cota C, Panetta C, Muscardin LM, Donati P. Early angiosarcoma of the scalp: a clinicopathological pitfall. Am J Dermatopathol. 2016; 38 (9): 690-694.

10. Choi JH, Ahn KC, Chang H, Minn KW, Jin US, Kim BJ. Surgical treatment and prognosis of angiosarcoma of the scalp: a retrospective analysis of 14 patients in a single institution. Biomed Res Int. 2015; 2015: 321896.

11. Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg. 1994; 168 (5): 451-454.

12. Morrison WH, Byers RM, Garden AS, Evans HL, Ang KK, Peters LJ. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer. 1995; 76 (2): 319-327.

13. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003; 98 (8): 1716-1726.

14. Köhler HF, Neves RI, Brechtbühl ER, Mattos Granja NV, Ikeda MK et al. Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. Otolaryngol Head Neck Surg. 2008; 139 (4): 519-524.

15. Patel SH, Hayden RE, Hinni ML, Wong WW, Foote RL, Milani S et al. Angiosarcoma of the scalp and face: the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg. 2015; 141 (4): 335-340.

16. Dettenborn T, Wermker K, Schulze HJ, Klein M, Schwipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study. J Craniomaxillofac Surg. 2014; 42 (8): 1623-1628.

17. Holloway CL, Turner AR, Dundas GS. Cutaneous angiosarcoma of the scalp: a case report of sustained complete response following liposomal Doxorubicin and radiation therapy. Sarcoma. 2005; 9 (1-2): 29-31.

18. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. J Dermatol. 2002; 147 (1): 150-153.

19. Miki Y, Tada T, Kamo R, Hosono MN, Tamiya H, Shimatani Y et al. Single institutional experience of the treatment of angiosarcoma of the face and scalp. Br J Radiol. 2013; 86 (1030): 20130439.

20. Ito T, Uchi H, Nakahara T, Tsuji G, Oda Y, Hagihara A et al. Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan. J Cancer Res Clin Oncol. 2016; 142 (6): 1387-1394.

21. Donghi D, Dummer R, Cozzio A. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. Br J Dermatol. 2010; 162 (3): 697-699.

22. Ono S, Tanioka M, Fujisawa A, Tanizaki H, Miyachi Y, Matsumura Y. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Arch Dermatol. 2012; 148 (6): 683-685.

23. Koontz BF, Miles EF, Rubio MA, Madden JF, Fisher SR, Scher RL et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008; 30 (2): 262-266.

24. Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol. 2010; 63 (4): e83-e84.

25. Yang P, Zhu Q, Jiang F. Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature. Chin J Cancer Res. 2013; 25 (3): 358-361.

26. De Yao JT, Sun D, Powell AT, Rehmus EH. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: a case report and review of the literature. Sarcoma. 2011; 2011: 160369.

27. Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol. 2015; 151 (11): 1226-1229.

28. Pasquier E, André N, Street J, Chougule A, Rekhi B, Ghosh J et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine. 2016; 6: 87-95.

29. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358 (24): 2649-2651.

30. Stiles JM, Amaya C, Rains S, Díaz D, Pham R, Battiste J et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013; 8 (3): e60021.

31. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4: 1403.

32. Ji G, Hong L, Yang P. Successful treatment of angiosarcoma of the scalp with apatinib: a case report. Onco Targets Ther. 2016; 9: 4989-4992.

33. Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27 (19): 3133-3140.

34. Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998; 153 (5): 1425-1433.